Episode Summary
In this TOGA podcast, we explore access to molecular diagnostics and treatments across ANZ: the past, present, future. Chaired by Prof Nick Pavlakis, who is joined by Dr Laird Cameron and Dr Renuka Chittajallu. The identification of molecular subtypes of non-squamous NSCLC continues to grow, spurring the development of targeted therapies designed to target these mutations and prevent the growth of the cancer. People with advanced NSCLC that possess one of these ‘actionable’ mutations and can access targeted treatments can live for many years with very manageable side effects. However, the technology to identify these actionable mutations in a single test and the targeted treatments are not yet accessible to all people with advanced NSCLC.
In Australia, the TOGA ASPiRATION study is evaluating the impact of providing comprehensive genomic profiling and access to targeted therapies, with the hope that this will provide the evidence for widespread reimbursement for testing and treatments for patients where an actionable mutation is identified.
https://thoraciconcology.org.au/aspiration/
Show Hosts
This episode’s host are:
- Prof Nick Pavlakis, Chair, TOGA; Senior Staff Specialist, Department of Medical Oncology, Royal North Shore Hospital
- Dr Laird Cameron, Medical Oncologist, Auckland Hospital and Canopy Cancer Care; TOGA Scientific Committee New Zealand representative
- Dr Renuka Chittajallu, Medical Oncologist Riverina Cancer Care Centre, Griffith Base Hospital, GenesisCare and Kingswood; Director of Clinical Trials, Riverina Cancer Care Centre
